



BSW Formulary Updates and Recent Decisions – September 2024

New additions to BSWformulary and Change in Traffic Light status

- [Macimorelin 60mg granules for oral suspension](#) – added with **RED TLS** for diagnostic use only; indicated for the diagnosis of growth hormone deficiency in adults.

New and Updated Prescribing Guidelines and Shared Care Agreements

- UPDATED - [AWP Guidance on Managing ADHD Medicines Shortages](#) (Adults & paediatrics). Updated AWP guidance now includes information to support primary care to make switches where necessary due to the national stock shortages, where they feel confident. The guide does not extend to use in patients under the care of CAMHS Oxford team who see paediatric patients with ADHD as well as other co-morbidities. For these patients, primary care prescribers should continue to contact CAMHS in the first instance.
- UPDATED – [BSW Atopic Dermatitis Pathway](#) – updated to include [lebrikizumab](#) in line with [NICE TA986](#)
- UPDATED – [BSW Emollient Prescribing Guidelines for Adults and Children](#) and [BSW Quick Guide – First Line Emollients](#) - updated to include [MHRA Drug Safety Update July 2024](#) which advises that **Epimax Ointment and Epimax Paraffin-Free Ointment can harm the eyes if used on the face**. Do not prescribe these ointments for use on the face. Tell patients to wash their hands and avoid touching their eyes after using these products. If this advice cannot reliably be followed, clinicians should choose a product that is suitable for use on the face e.g. White soft paraffin in liquid paraffin (50:50) or Hydromol ointment as a less greasy alternative. If patients experience any side effects from their medication, please encourage them to seek clinical advice and report to the MHRA via [yellow card scheme](#).

Minor amendments to Netformulary

- [Terlipressin and vasopressin injection](#). Indications removed from entries and replaced with note to use as per Trust policy. Choice of product has varied due to recent stock shortages.
- [AeroChamber Plus Flow-Vu Antistatic spacers](#) entry corrected to include all available sizes.
- [Ketotifen 0.25mg/ml single dose unit eyedrops](#) aligned for BSW with **AMBER TLS**.
- [Haloperidol 500microgram](#) tablet entries – non formulary in this strength. Reminder that 500microgram tablets cost £295.92/28 tablets on FP10. In primary care prescribers should follow OptimiseRx for cost-effective prescribing and use the oral solution where appropriate.
- [Proprantheline tablets 15mg](#) aligned for BSW with **GREEN TLS**.
- [LAT gel](#) aligned for use across BSW in line with internal Trust guidance. **RED TLS**.



- [Ajmaline](#) aligned for GWH and RUH for use in diagnosis of Brugada syndrome in line with Trust guidance. **RED TLS.**
- [Oral glucose](#) for the treatment of hypoglycaemia entry updated. Oral glucose products are used for managing acute hypoglycaemia in people who are able to swallow safely. **Patients/carers should routinely be advised to self-purchase oral glucose products (including jelly sweets, orange juice or full sugar carbonated drinks).** Specialist can advise or see NHS or Diabetes UK info (links below) for suggestions. If there is a history of severe hypos, and the clinician considers that an individual patient's ability to purchase a suitable oral glucose product is compromised (e.g. medical, mental health or social vulnerability) to the extent that their health and/or wellbeing could be adversely affected if they were reliant on self-care, it is permissible to issue on FP10. Formulary options include: Oral gel 40%, Lift fast acting glucose shot liquid, Lift chewable glucose tablets. Oral glucose products used within the acute Trust setting vary; consult internal policy.

What the BSW ICB formulary team are currently working on

- Updating Vitamin B12 guidance
- Writing a hypersalivation/drooling treatment pathway
- Writing a Shared Care Agreement for the use of rifampicin in bone infection
- Updating the overactive bladder pathway to include Vibegron in line with recently published NICE TA [Overview | Vibegron for treating symptoms of overactive bladder syndrome | Guidance | NICE](#)
- Review of acute migraine treatments and treatment pathway

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net